You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR ENTYVIO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ENTYVIO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00619489 ↗ Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease Completed Millennium Pharmaceuticals, Inc. Phase 2 2007-12-01 This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to receive treatment with vedolizumab, and to determine the long term safety of vedolizumab in patients afflicted with these diseases.
NCT00783692 ↗ Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease Completed Millennium Pharmaceuticals, Inc. Phase 3 2008-12-01 The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
NCT00783718 ↗ Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis Completed Millennium Pharmaceuticals, Inc. Phase 3 2009-01-01 The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
NCT01177228 ↗ Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis Completed Millennium Pharmaceuticals, Inc. Phase 2 2007-05-01 The main objectives of this study were to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of vedolizumab in patients with ulcerative colitis (UC).
NCT01224171 ↗ Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease Completed Millennium Pharmaceuticals, Inc. Phase 3 2010-11-01 This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ENTYVIO

Condition Name

Condition Name for ENTYVIO
Intervention Trials
Crohn's Disease 13
Ulcerative Colitis 12
Colitis, Ulcerative 7
Crohn Disease 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ENTYVIO
Intervention Trials
Crohn Disease 21
Colitis, Ulcerative 20
Colitis 18
Ulcer 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ENTYVIO

Trials by Country

Trials by Country for ENTYVIO
Location Trials
United States 260
Canada 34
Poland 19
Hungary 15
France 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ENTYVIO
Location Trials
Texas 15
New York 13
Washington 12
Illinois 12
Pennsylvania 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ENTYVIO

Clinical Trial Phase

Clinical Trial Phase for ENTYVIO
Clinical Trial Phase Trials
Phase 4 12
Phase 3 7
Phase 2 9
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ENTYVIO
Clinical Trial Phase Trials
Completed 14
Terminated 6
Recruiting 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ENTYVIO

Sponsor Name

Sponsor Name for ENTYVIO
Sponsor Trials
Takeda 24
Millennium Pharmaceuticals, Inc. 8
Geert D'Haens 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ENTYVIO
Sponsor Trials
Industry 36
Other 19
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.